JPMorgan analyst Anupam Rama said downside in shares of Sarepta this morning is overdone as he does not view the update on the company's ESSENCE trial as a major setback, noting the safety board has suggested the study can continue recruitment. Additionally, the case of rhabdomyolysis in a single patient on golodersin was coincident with an episode of a patient fall and the condition potentially could be muscle injury related, though a drug effect has not been completely ruled out yet, said Rama, who keeps an Overweight rating on Sarepta shares. Sarepta is submitting an amendment to resume dosing in the U.K., added Rama after having spoken with company management.